For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose:
The purpose of this study is to evaluate the efficacy and safety of pevonedistat plus azacitidine versus single-agent azacitidine in participants with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia and low-blast acute myelogenous leukemia.
Status:
Recruiting
Study Date:
Fri, 01/01/2016 to Fri, 12/01/2017
Bone Marrow Disease(s):
- myelodysplastic syndromes (MDS)
Associated Drug(s):
Intervention:
Drug: Azacitidine
Azacitidine intravenous or subcutaneous formulation.
Drug: Pevonedistat
Pevonedistat intravenous infusion.